Thrombospondin-1 inhibits alternative complement pathway activation in antineutrophil cytoplasmic antibody-associated vasculitis
Complement activation is a relevant driver in the pathomechanisms of vasculitis. The involved proteins in the interaction between endothelia, complement, and platelets in these conditions are only partially understood. Thrombospondin-1 (TSP-1), found in platelet α-granules and released from activated endothelial cells, interacts with factor H (FH) and vWF. However, to our knowledge, direct regulatory interaction with the complement cascade has not yet been described. Our study shows that TSP-1 is a potent, FH-independent inhibitor of the alternative complement pathway. TSP-1 binds to complement proteins and inhibits cleavage of C3 and C5 and the formation of the membrane attack complex. We validated complement-regulatory function in blood samples from patients with primary complement defects. The physiological relevance of TSP-1 was demonstrated in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV) by significantly enhanced TSP-1 staining in glomerular lesions and increased complement activity and NETosis after TSP-1 deficiency in an in vitro and in vivo model of AAV. The complement-inhibiting function of TSP-1 represents an important mechanism in the interaction of endothelia and complement. In particular, the interplay between released TSP-1 and the complement system locally, especially on surfaces, influences the balance between complement activation and inhibition and may be relevant in various vascular diseases.
Authors
- Swagata Konwar
- Christian Gorzelanny (ORCID: https://orcid.org/0000-0002-3788-6429)
- Barbara Zieger
- Robert Grosse (ORCID: https://orcid.org/0000-0002-3380-5273)
- Jens Panse (ORCID: https://orcid.org/0000-0001-6316-3112)
- Manuel Rogg (ORCID: https://orcid.org/0000-0002-6658-9159)
- Sophie Schroda
- Karsten Häffner (ORCID: https://orcid.org/0000-0003-2091-0784)
- Todor Tschongov (ORCID: https://orcid.org/0009-0005-8562-2662)
- Sílvia Vidal (ORCID: https://orcid.org/0000-0002-3909-6682)
- Christoph Schell (ORCID: https://orcid.org/0000-0001-5344-624X)
- Jessika Kleindienst
- Eva L. Decker (ORCID: https://orcid.org/0000-0002-9151-1361)
- Hong Wang (ORCID: https://orcid.org/0000-0003-0212-5379)
- Xiaobo Liu (ORCID: https://orcid.org/0000-0002-8256-6002)
- Martin Pöhl
Institutions
- Universität Hamburg (DE)
- University of Freiburg (DE)
- University Medical Center Freiburg (DE)
- Integrated Oncology (United States) (US)
- Okazaki Institute for Integrative Bioscience (JP)
- University Medical Center Hamburg-Eppendorf (DE)
- Office of Adolescent Health (US)
- Institute of Experimental Pharmacology and Toxicology of the Slovak Academy of Sciences (SK)
- Institute of Pharmacology (CZ)
- RWTH Aachen University (DE)
Publication Details
- Journal
- Journal of Clinical Investigation
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1172/jci180062
- Citations
- 4
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- Wilhelm Sander-Stiftung
- Deutsche Forschungsgemeinschaft
- Albert-Ludwigs-Universität Freiburg
- Medizinische Fakultät der Albert-Ludwigs-Universität Freiburg